Skip to content

Laboratoire Avédis

Active
Private limited companyfounded 2023active for 3 yearsRue Haute(NSV) 85, 1457 Walhain, BelgiumKBO/BCE: BE 1001.178.669

From the official registers: KBO 2 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Laboratoire Avédis has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €71,020 and a net result of -€1,116. Its solvency ranks better than 95% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Official details

KBO
Status
Active since 13-10-2023 Normal situation
Legal form
Private limited company
Registered office
Rue Haute(NSV) 85, 1457 Walhain
Activity
Research and development on biotechnology NACE 72101
Establishment unit
2.353.701.040 1457 Walhain, since 13-10-2023
Financial year end
31 December
Peppol
Not found in the Peppol Directory

Board and ownership

Board

Financial position

95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Annual accounts 2025
Gross margin
-€583
▲ 91.1%
Loss
€1,116
▼ 85.8%
Equity
€71,020
▼ 1.5%
Total assets
€72,270
▼ 57.1%
2025 accounts filed 28 days after the deadline
Filed on 28-08-2026at the National Bank
Score breakdownraises riskFounded in 2023lowers riskLiquidity: current ratio 57.67, cash €72,085, halvedSector: Scientific research and development (NACE 72)Equity €71,020 (98.3% of total assets)Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 63% of micro companies in research and development (NACE 72)
Financial strength · tick: 2024
Strong
Solvency 100+32
equity 98.3% of total assets
Liquidity 100=
short-term debt 1.7% · cash 99.7%
Profitability 34+8
return on assets -1.5%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (935 companies, NACE 72, micro)
Last 24 months 11-2024: 0.7% 12-2024: 0.7%● unchanged vs 11-2024 01-2025: 0.7%● unchanged vs 12-2024 02-2025: 0.8%▲ +0.1 percentage points vs 01-2025 03-2025: 0.8%● unchanged vs 02-2025 04-2025: 0.9%▲ +0.1 percentage points vs 03-2025 05-2025: 1.0%▲ +0.1 percentage points vs 04-2025 06-2025: 1.0%● unchanged vs 05-2025 07-2025: 1.0%● unchanged vs 06-2025 08-2025: 1.0%● unchanged vs 07-2025 09-2025: 1.0%● unchanged vs 08-2025highest value 10-2025: 0.1%▼ -0.9 percentage points vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.2%▲ +0.1 percentage points vs 07-2026 09-2026: 0.1%▼ -0.1 percentage points vs 08-2026lowest value 10-2026: 0.1%● unchanged vs 09-2026lowest value
Credit of up to €6,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 57.67, above the usual 1.5. Short-term debt is 1.7% and cash 99.7% of total assets. 1.7% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 83% of them on solvency, 96% on liquidity, 32% on profitability and 43% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises risk
lowers risk · Liquidity: current ratio 57.67, cash €72,085, halved
NBB · annual accounts
lowers risk · Sector: Scientific research and development (NACE 72)
KBO
raises risk · Founded in 2023
Companies of this age fail more often than older ones. How much that weighs depends on the rest of the company's profile.
KBO
lowers risk · Equity €71,020 (98.3% of total assets)
NBB · annual accounts
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
2425
2024 to 2025 · latest year -€1,116
raises risk · 2025 accounts filed 28 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 2 filings
Deviation from the deadline
2025
28 days late
2024
29 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 2 accounts on average 29 days after the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2023.
KBO publications

Key points

  • Positive: Higher solvency than 95% of companies in research and developmentsector median 45.5% · 271 companies 98.3% View

Documents

Annual accounts at the NBB

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about Laboratoire Avédis

What is the company number of Laboratoire Avédis?
The company number of Laboratoire Avédis is 1001.178.669. The VAT number is the same number with BE in front: BE 1001.178.669.
Where is Laboratoire Avédis based?
The registered office is at Rue Haute(NSV) 85, 1457 Walhain.Company details
What does Laboratoire Avédis do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of Laboratoire Avédis?
The legal form of Laboratoire Avédis is Private limited company (BV).
When was Laboratoire Avédis founded?
Laboratoire Avédis was founded on 13-10-2023.
Is Laboratoire Avédis still active?
Yes, Laboratoire Avédis is an active enterprise in the KBO register.
What is the turnover of Laboratoire Avédis?
The annual accounts for financial year 2025 state no turnover.Financials
Is Laboratoire Avédis profitable?
In financial year 2025, Laboratoire Avédis made a loss of €1,116.
Where can I find the annual accounts of Laboratoire Avédis?
Laboratoire Avédis filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of Laboratoire Avédis due?
Laboratoire Avédis must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Comparable companies

These companies have the same main activity as Laboratoire Avédis: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €34,600 and €112,000, founded between 2021 and 2024.

CompanyTotal assetsGross margin
Laboratoire Avédis Walhain€72,270-€583
Benno Therapeutics Leuven€56,724-€194,008
NCD Consultants Overijse€55,512-€15,605
pEGGY Gent€111,705-€77,583
Sealantium Medical Belgium Diepenbeek€56,033-€7,311
POLYPHEMUS Watermaal-Bosvoorde€34,603-€1,035
JN-RD Oreye€67,834-€653
Full comparison

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.